ELAN Stock Forecast & Price Target

Elanco Animal Health is supported by a strengthening new-product cycle, with Befrena generating strong early clinic adoption, 83% of vets likely to use it, and demand running well above expectations as capacity expands. Its 2Q results reinforced operational momentum, as revenue of $1,368M, adjusted EBITDA of $288M, and adjusted EPS of $0.34 all topped consensus, while FY26 guidance was raised for revenue, organic constant-currency growth, EBITDA, and EPS. The outlook is further underpinned by a diversified global franchise in pet health and farm animal products, pricing power in key categories, and confidence in a pipeline of five to six blockbuster potential innovations and seven potential blockbuster launches through 2031.

Elanco Animal Health is facing a weak fundamental setup driven by weather-sensitive demand, regulatory and pipeline uncertainty, and competition that could erode confidence and limit growth. Slower sales ramps for its 7 key blockbusters, rising cannibalization, and commoditization in K9 derm and parasiticide markets could pressure sales and EPS below expectations, while K9 population growth is assumed to remain only 0.0%-0.3% and U.S. broad-spectrum endecto volume growth slows from 29% to 3%. Additional headwinds include EU and U.S. LOE exposure on key products, generic pressure, competitive label differentiation, foreign exchange, and emerging-market economic and political uncertainty.